Non-Classical Sources of Tumour-Specific Antigen in Checkpoint Inhibitor Response

About the webinar

In recent years, research around immunotherapy as an avenue for cancer treatment (otherwise known as immuno-oncology) has increased rapidly, with a focus on discovering biomarkers associated with checkpoint inhibitor (CPI) response. However, immune response can vary from patient-to-patient, presenting challenges for therapeutic development.

To better understand the diversity of immune response to cancer, researchers at UCL Cancer Institute leveraged previously published research as well as performed exploratory research using a multiomics approach including whole exome sequencing (WES) and RNA sequencing (RNA-Seq) on a cohort of more than 1000 patients with varying cancer types.

In this webinar, Kevin Litchfield, Ph.D., Group Leader at UCL Cancer Institute, presents their research, including their findings of an alternative source of a tumor-specific antigen in CPI response.

What you'll learn about

• Breakdown of cancer/drug type and biomarker correlation
• What factors are we missing in CPI response?
• INDELs as a biomarker
• High-quality epitopes as a new immunotherapeutic
• Q&A with Dr. Litchfield